Immunitybio is trading 6.24% down at $8.28, alongside broad market weakness; no clear company-specific announcement explaining the October 30 move surfaced.
- A market report said there were no Immunitybio headlines for the date.
- A Friday market update showed the Nasdaq down 2.1% and the S&P 500 down 1.3%. This broader weakness may have contributed, but reports do not establish a direct cause for Immunitybio’s intraday drop.